Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $35.67 Average Price Target from Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $35.67.

Several equities analysts have weighed in on VIR shares. Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, February 28th. Barclays increased their target price on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, February 28th. JPMorgan Chase & Co. boosted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Finally, Leerink Partners increased their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th.

Insider Activity

In other Vir Biotechnology news, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the transaction, the director now owns 708,295 shares in the company, valued at $6,948,373.95. This trade represents a 1.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the sale, the executive vice president now owns 79,460 shares of the company’s stock, valued at approximately $726,264.40. The trade was a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,859 shares of company stock valued at $326,458 over the last quarter. Company insiders own 15.60% of the company’s stock.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors have recently added to or reduced their stakes in VIR. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vir Biotechnology in the 4th quarter worth about $42,000. SBI Securities Co. Ltd. acquired a new stake in Vir Biotechnology during the 4th quarter worth approximately $60,000. PNC Financial Services Group Inc. raised its holdings in Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after buying an additional 1,999 shares during the period. KBC Group NV lifted its position in Vir Biotechnology by 136.5% during the fourth quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after buying an additional 5,177 shares in the last quarter. Finally, CIBC Asset Management Inc purchased a new stake in Vir Biotechnology during the fourth quarter worth approximately $74,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $8.07 on Tuesday. Vir Biotechnology has a 12 month low of $6.56 and a 12 month high of $14.45. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.06 and a beta of 1.17. The business’s 50 day simple moving average is $9.51 and its 200-day simple moving average is $8.48.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. The company had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. On average, equities analysts anticipate that Vir Biotechnology will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).